Dosing of Ropinirole Prolonged Release in Parkinson's Disease
Dosing of Ropinirole Prolonged Release in Parkinson's Disease
In this study, RPR was able to achieve improvement over the IR form of agonists. Twice-daily RPR was preferred over once-daily dosing in many patients.
This study has limitations as an open-label trials and pharmacodynamical study was not done. However, multiple dosing of RPR might be considered a therapeutic option if once-daily dosing is unsatisfactory. Greater satisfaction with twice-daily RPR may lead to achieving good compliance and improving outcomes.
In response to the final preference questionnaire, 28% (n = 17) of the patients preferred the once-daily regimen, 51% (n = 31) preferred the twice-daily regimen, and 21% (n = 21) did not have a preference.
Conclusions
In this study, RPR was able to achieve improvement over the IR form of agonists. Twice-daily RPR was preferred over once-daily dosing in many patients.
This study has limitations as an open-label trials and pharmacodynamical study was not done. However, multiple dosing of RPR might be considered a therapeutic option if once-daily dosing is unsatisfactory. Greater satisfaction with twice-daily RPR may lead to achieving good compliance and improving outcomes.
In response to the final preference questionnaire, 28% (n = 17) of the patients preferred the once-daily regimen, 51% (n = 31) preferred the twice-daily regimen, and 21% (n = 21) did not have a preference.
Source...